Clear All

Showing results 361-370 / 1232

Driving pharmaceutical innovation

JM's Vice President Innovator Products and Solutions, Nick Shackley, discusses advanced catalytic activity, combining technologies with collaborations and more.

Explore

Johnson Matthey Chemist Wins Prestigious Royal Society of Chemistry Prize

Johnson Matthey Chemist Wins Prestigious Royal Society of Chemistry Prize

Explore

Johnson Matthey enters into New Relationship with Anglo Platinum

Johnson Matthey enters into New Relationship with Anglo Platinum

Explore

Johnson Matthey Appoints New Non-Executive Director

Johnson Matthey Plc is pleased to announce the appointment of Christopher Mottershead as a non-executive director of the company with effect from 27th January 2015

Explore

Johnson Matthey Completes Sale of Gold and Silver Refining business to Asahi

Johnson Matthey has sold its Gold and Silver Refining business to Asahi, a collector, refiner and recycler of precious and rare metals from waste materials

Explore

Johnson Matthey Completes Sale of Research Chemicals (Alfa Aesar) Business to Thermo Fisher Scientific Inc.

This completes the transaction which was first announced on 25th June 2015

Explore

JM launches first virtual work experience programme

News: With the support of social mobility charity, Speakers for Schools, JM welcomed 115 students from across the UK to its first virtual work experience programme.

Explore

Honouring the work of our people at our first global awards ceremony

News: To mark the end of our 200th year, we hosted an internal awards ceremony to honour the incredible work and achievements of several JM employees from across the globe.

Explore

JM methanol technology chosen for largest single train methanol plant in the world

News: JM has been selected by China’s Ningxia Baofeng Energy Group as licensor for the third methanol synthesis plant at their coal to olefins complex near Yinchuan in Ningxia Province PRC.

Explore

Early form screening strategies to accelerate candidate selection

A whitepaper featuring a solid form expert, detailing early form screening strategies for pharmaceutical development and the importance of understanding an API’s solid form for formulation development.

Explore